Maintenance of the synergistic effects of cord blood cells and erythropoietin combination therapy after additional cord blood infusion in children with cerebral palsy: 1-year open-label extension study of randomized placebo-controlled trial
Tóm tắt
This 1-year open-label extension study aimed to identify the persistent synergistic effects of allogeneic umbilical cord blood (UCB) cells and erythropoietin (EPO) in children with cerebral palsy (CP) for up to 2 years. This open-label extension study followed children with CP who were enrolled in the previous randomized, double blind, placebo-controlled trial. The following groups from the first trial were maintained: (A) UCB + EPO, (B) UCB, (C) EPO, and (D) only placebo, and all the participants had continued active rehabilitation. This extended study started 3 months after termination of the first trial, which had a 1-year follow-up duration. All subjects received single additional UCB intravenous infusion at the extension baseline regardless of their initial allocation. Outcome measures were the gross motor performance measure (GMPM), gross motor function measure-66 (GMFM-66), and Bayley scales of infant development-II (BSID-II), which were followed at 3, 6, and 12 months after the extension baseline. Changes in the outcome scores from the baseline values of the previous trial and this study were analysed. Sixty-nine children (4.29 ± 1.28 years, M:F = 34:35) were included in this study. Each group showed improvements in the outcome measures at 12 months after additional UCB infusion compared to the baseline scores, except for GMFM and GMPM in Group C which were elevated at 3 and 6 months post-therapy. Total subject analyses did not show significant differences in the outcome measures between the four different groups at 3, 6 and 12 months after additional UCB therapy. However, patients with severe dysfunction, whose GMFCS levels were IV and V, revealed a larger improvement of the GMPM score in Group A than in Group D (Ps < 0.05) from the baseline value of the previous trial. The changes in BSID-II mental scale scores were positively correlated with the number of administered total nucleated cells per unit body weight during this one-year extension study period (r = 0.536, P = 0.001). These results suggest that when administering UCB to treat patients with CP, combination therapy with EPO is more effective, and the effect might last as long as 2 years, especially in patients with severe impairments. Trial registration: CHA Bundang Medical Center IRB, No. 2015–06-093, approved on July 29, 2015, (
https://www.e-irb.com:3443/devlpg/nlpgS200.jsp
), ClinicalTrials.gov, NCT03130816, retrospectively registered on April 27, 2017 (
https://clinicaltrials.gov/ct2/show/NCT03130816?term=NCT03130816&draw=2&rank=1
).
Tài liệu tham khảo
Aisen ML, Kerkovich D, Mast J, Mulroy S, Wren TA, Kay RM, Rethlefsen SA. Cerebral palsy: clinical care and neurological rehabilitation. Lancet Neurol. 2011;10(9):844–52.
Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, Jacobsson B, Damiano D. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol. 2005;47(8):571–6.
Colver A, Fairhurst C, Pharoah PO. Cerebral palsy. Lancet (Lond, Engl). 2014;383(9924):1240–9.
Rosenbaum PL, Walter SD, Hanna SE, Palisano RJ, Russell DJ, Raina P, Wood E, Bartlett DJ, Galuppi BE. Prognosis for gross motor function in cerebral palsy: creation of motor development curves. JAMA. 2002;288(11):1357–63.
Hanna SE, Rosenbaum PL, Bartlett DJ, Palisano RJ, Walter SD, Avery L, Russell DJ. Stability and decline in gross motor function among children and youth with cerebral palsy aged 2 to 21 years. Dev Med Child Neurol. 2009;51(4):295–302.
Sun JM, Song AW, Case LE, Mikati MA, Gustafson KE, Simmons R, Goldstein R, Petry J, McLaughlin C, Waters-Pick B. Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: a randomized, placebo-controlled trial. Stem Cells Transl Med. 2017;6(12):2071–8.
Feng M, Lu A, Gao H, Qian C, Zhang J, Lin T, Zhao Y: Safety of allogeneic umbilical cord blood stem cells therapy in patients with severe cerebral palsy: a retrospective study. Stem cells international 2015, 2015.
Romanov YA, Tarakanov OP, Radaev SM, Dugina TN, Ryaskina SS, Darevskaya AN, Morozova YV, Khachatryan WA, Lebedev KE, Zotova NS. Human allogeneic AB0/Rh-identical umbilical cord blood cells in the treatment of juvenile patients with cerebral palsy. Cytotherapy. 2015;17(7):969–78.
Min K, Song J, Kang JY, Ko J, Ryu JS, Kang MS, Jang SJ, Kim SH, Oh D, Kim MK. Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: A double-blind, randomized, placebo-controlled trial. Stem Cells. 2013;31(3):581–91.
Kang M, Min K, Jang J, Kim SC, Kang MS, Jang SJ, Lee JY, Kim SH, Kim MK, An SA. Involvement of immune responses in the efficacy of cord blood cell therapy for cerebral palsy. Stem Cells Dev. 2015;24(19):2259–68.
Jiao Y. Li X-y, Liu J: A new approach to cerebral palsy treatment: discussion of the effective components of umbilical cord blood and its mechanisms of action. Cell Transp. 2019;28(5):497–509.
McDonald CA, Fahey MC, Jenkin G, Miller SL. Umbilical cord blood cells for treatment of cerebral palsy; timing and treatment options. Pediatr Res. 2018;83(1):333–44.
Liu W-S, Chen C-T, Foo N-H, Huang H-R, Wang J-J, Chen S-H, Chen T-J. Human umbilical cord blood cells protect against hypothalamic apoptosis and systemic inflammation response during heatstroke in rats. Pediatr Neonatol. 2009;50(5):208–16.
Fleiss B, Gressens P. Tertiary mechanisms of brain damage: a new hope for treatment of cerebral palsy? Lancet Neurol. 2012;11(6):556–66.
Jing M, Shingo T, Yasuhara T, Kondo A, Morimoto T, Wang F, Baba T, Yuan WJ, Tajiri N, Uozumi T. The combined therapy of intrahippocampal transplantation of adult neural stem cells and intraventricular erythropoietin-infusion ameliorates spontaneous recurrent seizures by suppression of abnormal mossy fiber sprouting. Brain Res. 2009;1295:203–17.
Rah W-J, Lee Y-H, Moon J-H, Jun H-J, Kang H-R, Koh H, Eom HJ, Lee JY, Lee YJ, Kim JY. Neuroregenerative potential of intravenous G-CSF and autologous peripheral blood stem cells in children with cerebral palsy: a randomized, double-blind, cross-over study. J Transl Med. 2017;15(1):1–9.
Papadopoulos K, Low S, Aw T, Chantarojanasiri T. Safety and feasibility of autologous umbilical cord blood transfusion in 2 toddlers with cerebral palsy and the role of low dose granulocyte-colony stimulating factor injections. Restor Neurol Neurosci. 2010;28:1–6.
Min K, Suh MR, Cho KH, Park W, Kang MS, Jang SJ, Kim SH, Rhie S, Choi JI, Kim H-J. Potentiation of cord blood cell therapy with erythropoietin for children with CP: a 2× 2 factorial randomized placebo-controlled trial. Stem Cell Res Ther. 2020;11(1):1–12.
Liu W, Shen Y, Plane JM, Pleasure DE, Deng W. Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia. Exp Neurol. 2011;230(2):227–39.
Choi JI, Choi J-W, Shim K-H, Choung JS, Kim H-J, Sim HR, Suh MR, Jung JE, Kim M. Synergistic effect in neurological recovery via anti-apoptotic akt signaling in umbilical cord blood and erythropoietin combination therapy for neonatal hypoxic-ischemic brain injury. Int J Mol Sci. 2021;22(21):11995.
Huang L, Zhang C, Gu J, Wu W, Shen Z, Zhou X, Lu H. A randomized, placebo-controlled trial of human umbilical cord blood mesenchymal stem cell infusion for children with cerebral palsy. Cell Transp. 2018;27(2):325–34.
Gu J, Huang L, Zhang C, Wang Y, Zhang R, Tu Z, Wang H, Zhou X, Xiao Z, Liu Z. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Res Ther. 2020;11(1):1–12.
Cho K, Min K, Lee S, Kim M. Safety and efficacy of allogeneic umbilical cord blood therapy combined with erythropoietin in children with cerebral palsy: study protocol for a double-blind, randomized, placebo-controlled trial. Asia Pac J Clin Trials Nervous Syst Dis. 2017;2(4):129–129.
Rubinstein P, Dobrila L, Rosenfield RE, Adamson JW, Migliaccio G, Migliaccio AR, Taylor PE, Stevens CE. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci. 1995;92(22):10119–22.
Ko J, Kim M. Reliability and responsiveness of the gross motor function measure-88 in children with cerebral palsy. Phys Ther. 2013;93(3):393–400.
Ko J, Kim M. Inter-rater reliability of the K-GMFM-88 and the GMPM for children with cerebral palsy. Ann Rehabil Med. 2012;36(2):233–9.
Lee JH, Lim HK, Park E, Song J, Lee HS, Ko J, Kim M. Reliability and applicability of the Bayley scale of infant development-II for children with cerebral palsy. Ann Rehabil Med. 2013;37(2):167–74.
Wysoczynki M, Khan A, Bolli R. New paradigms in cell therapy: repeated dosing, intravenous delivery, immunomodulatory actions, and new cell types. Circ Res. 2018;123(2):138–58.
Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54–63.
Cyclosporine [https://medlineplus.gov/druginfo/meds/a601207.html]
Oeffinger D, Bagley A, Rogers S, Gorton G, Kryscio R, Abel M, Damiano D, Bames D, Tylkowski C. Outcome tools used for ambulatory children with cerebral palsy: responsiveness and minimum clinically important differences. Dev Med Child Neurol. 2008;50(12):918–25.
Choi J-W, Kang SJ, Choi JI, Kwack K, Kim M. Role of nuclear-receptor-related 1 in the synergistic neuroprotective effect of umbilical cord blood and erythropoietin combination therapy in hypoxic ischemic encephalopathy. Int J Mol Sci. 2022;23(5):2900.
Bayley N. Bayley scales of infant development (BSID-II). San Antonio, TX: Psychological Corporation; 1993.